Ferguson Wellman Capital Management Inc. Invests $50,000 in NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO)

Ferguson Wellman Capital Management Inc. purchased a new position in NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) during the third quarter, HoldingsChannel.com reports. The fund purchased 15,670 shares of the company’s stock, valued at approximately $50,000.

Separately, Affinity Asset Advisors LLC acquired a new stake in shares of NeuroBo Pharmaceuticals in the 2nd quarter worth about $432,000. 1.37% of the stock is currently owned by hedge funds and other institutional investors.

NeuroBo Pharmaceuticals Trading Down 6.6 %

Shares of NASDAQ:NRBO opened at $2.39 on Friday. The company’s 50-day moving average price is $2.98 and its 200 day moving average price is $3.68. NeuroBo Pharmaceuticals, Inc. has a fifty-two week low of $2.08 and a fifty-two week high of $6.75.

NeuroBo Pharmaceuticals (NASDAQ:NRBO) last issued its quarterly earnings data on Wednesday, August 14th. The company reported ($1.85) earnings per share for the quarter, missing the consensus estimate of ($1.38) by ($0.47). As a group, research analysts forecast that NeuroBo Pharmaceuticals, Inc. will post -4.39 EPS for the current year.

About NeuroBo Pharmaceuticals

NeuroBo Pharmaceuticals, Inc, a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity.